Allogene Therapeutics ALLO Convertible Preferred Stock Authorized Shares
Convertible Preferred Stock Authorized Shares at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's convertible preferred stock authorized shares.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's convertible preferred stock authorized shares?
- Allogene Therapeutics (ALLO) reported convertible preferred stock authorized shares of 10M in Q1 2026.
- How has Allogene Therapeutics's convertible preferred stock authorized shares changed year-over-year?
- Allogene Therapeutics's convertible preferred stock authorized shares decreased by 0.0% year-over-year, from 10M to 10M.
- What is the long-term trend for Allogene Therapeutics's convertible preferred stock authorized shares?
- Over 5 years (2020 to 2025), Allogene Therapeutics's convertible preferred stock authorized shares has grown at a 0.0% compound annual growth rate (CAGR), from 10M to 10M.
- What does convertible preferred stock authorized shares mean?
- Maximum number of convertible preferred shares the company is authorized to issue under its corporate charter.